Yea, though I walk through the valley of the shadow of death, I...

Yea, though I walk through the valley of the shadow of death, I fear, no subscription.
...or maybe not enough. Bluegens are selling well I see (another CSIRO success story harvested by others). DYE's fallen perovskite dream grinds on with reported experimental efficiencies up around 25% now, tandems close to 30% but not in market. Fair cop on that one, mea culpa.
RFX though has a working battery that is painfully close to supporting a profitable company. The perennial chestnut, commercialising new tech in Oz. I have a committed % of total wealth I don't care if I lose because sometimes I win in this space. Rules. Nil Thai scale up at 50% is a bit existential.